<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501435</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_FEN_101</org_study_id>
    <nct_id>NCT01501435</nct_id>
  </id_info>
  <brief_title>To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra</brief_title>
  <official_title>A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives

        -  To compare the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra after
           a single oral administration in healthy male volunteers.

        -  To evaluate the food-effect on pharmacokinetics of CJ-30039 after a single oral
           administration in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of fenofibric acid</measure>
    <time_frame>up to 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fenofibric acid</measure>
    <time_frame>up to 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-30039</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Incrementally Modified Drugs of fenofibric acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fenofibric acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Greencross Lipidil Supra 160mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30039</intervention_name>
    <description>single dose</description>
    <arm_group_label>CJ-30039</arm_group_label>
    <other_name>Incrementally Modified Drugs of fenofibric acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibric acid</intervention_name>
    <description>single dose</description>
    <arm_group_label>fenofibric acid</arm_group_label>
    <other_name>Greencross Lipidil Supra 160mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 55 years old

          -  BMI(Body Mass Index) in the range of 18.5 to 25kg/m2

          -  Subject with no history of any significant chronic disease

        Exclusion Criteria:

          -  History of clinically significant allergies, including fenofibric acid or Fenofibrate

          -  History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary,
             endocrine, hematologic, cardiovascular disease

          -  History of surgery except or gastrointestinal disease which might significantly change
             absorption of medicines

          -  Clinical laboratory test values are outside the accepted normal range

               -  AST(ASpartate Transaminase), ALT(ALanine Transaminase)( &gt; 1.25 times to normal
                  range

               -  Total bilirubin &gt; 1.5 times to normal range

               -  BUN(Blood Urea Nitrogen) &gt; 25 mg/dL or Creatinine &gt; 1.4 mg/dL

               -  CK(Creatine Kinase) &gt; 1.25 times to normal range

          -  Estimated GFR(Glomerular Filtration Rate) &lt; 80 mL/min/1.73m2

          -  Clinically significant vital sign

               -  SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 150 mmHg

               -  DBP(Diastolic Blood Pressure) ≤ 50 mmHg or DBP ≥ 100 mmHg

          -  History of drug abuse or positive urine screen for drugs

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine &gt; 5 cups/day

               -  alcohol &gt; 201g/week

               -  smoking &gt; 10 cigarettes/day

          -  Use of prescription only medicine and oriental medicine within the 14 days before
             dosing or use of non-prescription medicine within the 7 days before dosing

          -  Participated in a previous clinical trial within 60 days prior to dosing

          -  Donated blood within 60 days prior to dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-su Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei university severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibric acid</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

